What our first 20 MINX 5 mg users reported about side effects, compared head-to-head with the published 5 mg oral minoxidil study and against low-dose oral minoxidil across 1,404 patients. A consumer perception study, not a clinical trial.
We asked our first MINX users a simple question: how does it feel to take? This is an early look at what they told us about tolerability, set honestly against the published safety record of oral minoxidil. It is a consumer perception study, not a clinical trial, and it makes no claim about hair regrowth.
Matched on the same 5 mg dose, the systemic picture is similar and low. There were no serious cardiovascular events in either group, and swelling in 1 of our 20 users (5%) versus 10% in the study. Both groups are small and ours is self-reported, so read this as a context check, not a controlled trial.
MINX 5 mg (our first 20) vs oral minoxidil 5 mg (study, 30 men)
The 5 mg comparison comes from Panchaprateep and Lueangarun 2020, which treated 30 men with oral minoxidil 5 mg once daily for 24 weeks, monitored with exams and labs. It found no serious cardiovascular events and no abnormal lab results, though extra body hair (hypertrichosis) was very common at 5 mg.
None of our 20 users reported a cardiovascular symptom. The largest safety study of oral minoxidil followed 1,404 patients at a mean dose of just 1.63 mg, about a third of a 5 mg capsule (Vañó-Galván 2021). The cardiovascular symptoms people worry about, a fast heart rate or dizziness, showed up in about 2.6% of those low-dose patients. Among our 20 users on the higher 5 mg dose, none reported a cardiovascular symptom at all.
MINX 5 mg vs low-dose oral minoxidil, measured across 1,404 patients
That is the effect a smooth, lower-peak curve is designed to blunt, though 20 self-reports are far too few to prove it, and swelling did still occur (above).
Across every systemic symptom, our 5 mg users landed right where the low-dose data sits. Widen the lens from the heart to any systemic symptom, a fast heart rate, dizziness, swelling, or headache, and one person in our group of 20 (5%) reported any of these. In the 1,404-patient low-dose study, those same symptoms summed to about 4.6%. So even though our users are on the higher 5 mg dose, their overall rate of systemic symptoms sits alongside the low-dose figure measured across far more people. Our 5% is still a single person, so treat it as directional, not proof.
Fast heart rate, dizziness, swelling, or headache
This is early, small, self-reported feedback, and it should be read that way. The honest caveats, in one place:
Among the first 20 users on MINX 5 mg, about 3 in 4 (75%) reported no side effects and 1 in 20 (5%) flagged a symptom they considered serious. No one reported a cardiovascular symptom. This is early, self-reported feedback, not a clinical trial, with no claim about hair regrowth.
In the study that used 5 mg once daily in 30 men over 24 weeks, there were no serious cardiovascular events and no abnormal labs, though extra body hair was very common (93%). Oral minoxidil is not FDA-approved for hair loss and is prescribed off-label under clinician guidance.
Hypertrichosis, meaning extra hair growth on the body, was the most frequent effect at 5 mg, affecting 93% of men in the published study. It is cosmetic rather than dangerous and often eases with a dose change. Our check-in did not specifically measure it.
No. Our early feedback is consistent with the published safety record of oral minoxidil, but a small self-reported consumer perception study cannot show that one form is safer than another. Only a controlled head-to-head trial could answer that question.
MINX is smooth-release oral minoxidil, a 503A compounded capsule. It is designed to release the same total daily dose more slowly, so it is modeled to reach a lower peak later in the day rather than a fast, high spike. It is prescribed off-label after a clinician evaluation.
The short answer: Among the first 20 MINX 5 mg users, about 3 in 4 (75%) reported no side effects at all, 1 in 20 (5%) flagged a symptom they considered serious, and none reported a cardiovascular symptom like a fast heart rate or dizziness. That early, self-reported picture is consistent with the published safety record of oral minoxidil, which is well tolerated at hair-loss doses. This is a small consumer perception study, not a clinical trial, and it makes no efficacy claims.
MINX is smooth-release oral minoxidil, a 503A compounded capsule. It is not an FDA-approved product. A clinician evaluates you first, and if oral minoxidil is appropriate, a formulation is compounded and prescribed for you off-label, at an individualized dose. It is designed to release the same total daily dose more slowly, so it is modeled to reach a lower peak, later in the day, rather than a fast, high spike. Because oral minoxidil's side effects might track with dose and blood level, that curve is the whole point.
Educational only, not medical advice. MINX is compounded oral minoxidil, not an FDA-approved product, and is prescribed off-label after a clinician evaluation. This check-in was emailed to about 160 MINX customers, and the MINX figures in this article summarize only the 20 responses we received; because respondents chose to reply, they may not represent every MINX user. The figures above describe early self-reported customer feedback and published studies; they are not proof of safety or efficacy for any individual.